The End of the Digoxin Era?
Keywords:
digitalis, digoxin, atrial fibrillation, heart failure, mortality, proarrhythmia, digoxin toxicityAbstract
Digoxin is one of the oldest of cardiovascular drugs which is still frequently used, both in patients with atrial fibrillation (AF) and patients with heart failure with or without AF. The use of digoxin preceded the era of evidence based medicine. However, over the recent past, there has been growing evidence disputing and challenging the safety and efficacy of digoxin, while evidence has accumulated that a plethora of other therapies for both heart failure and atrial tachyarrhythmias has proven more effective and safe. Nevertheless, digoxin still retains its role, albeit limited, in the current era, but most recent evidence has cast significant doubts about its safety. Thus, its role remains controversial and the drug should be reserved for specific patients and clinical scenarios, with careful monitoring of its serum concentration due to its narrow therapeutic and toxic ranges, maintaining it <0.8 ng/mL, with additional monitoring of serum electrolytes and renal function to avoid potential confounders that may enhance the proarrhythmic risk and susceptibility to digoxin toxicity.
Downloads
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).